TCGA-A8-A07C-01A-11R-A034-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 34
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.610
- G2M_CHECKPOINT+0.590
- MYC_TARGETS_V1+0.450
- MITOTIC_SPINDLE+0.340
- MYC_TARGETS_V2+0.310
- SPERMATOGENESIS+0.290
- PROTEIN_SECRETION+0.250
- UNFOLDED_PROTEIN_RESPONSE+0.220
- MTORC1_SIGNALING+0.210
- ALLOGRAFT_REJECTION+0.160
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.470
- INTERFERON_ALPHA_RESPONSE-0.460
- ESTROGEN_RESPONSE_LATE-0.440
- MYOGENESIS-0.390
- COAGULATION-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- APICAL_SURFACE-0.330
- P53_PATHWAY-0.310
- XENOBIOTIC_METABOLISM-0.300
- APOPTOSIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 63f6d3e9-3f4b-44fa-8e48-980c70b7e4f1 | — | — | 0.881 |
| 2 | TCGA-AR-A1AH-01A-11R-A12D-07 | — | E | 0.881 |
| 3 | TCGA-85-6560-01A-11R-1820-07 | — | cohortMD1 | 0.878 |
| 4 | TCGA-A1-A0SO-01A-22R-A084-07 | — | E | 0.872 |
| 5 | TCGA-78-7155-01A-11R-2039-07 | — | cohortMD1 | 0.866 |
| 6 | BS_TV5B86ZD | Embryonal tumors | — | 0.861 |
| 7 | SRR12475130 | — | — | 0.856 |
| 8 | SRR11296736 | — | — | 0.855 |
| 9 | TCGA-AC-A2BK-01A-11R-A21T-07 | — | E | 0.853 |
| 10 | SRR934937 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.610 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |